RET, ret proto-oncogene, 5979

N. diseases: 607; N. variants: 162
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Metastatic malignant neoplasm to brain
0.060 GeneticVariation disease BEFREE An EGFR mutation, and ALK and RET gene fusions are risk factors for brain metastasis in advanced NSCLC patients. 31769228 2020
Metastatic malignant neoplasm to brain
0.060 Biomarker disease BEFREE Small molecule inhibition of RET and HER2 in ex vivo patient BrM models (n = 4) resulted in statistically significantly reduced proliferation (P < .001 in four of four models). 29961873 2019
Metastatic malignant neoplasm to brain
0.060 Biomarker disease BEFREE The cumulative incidence of brain metastases was significantly different (p = 0.0039) between RET-, ROS1-, and ALK receptor tyrosine kinase (ALK)-rearranged lung cancers, with RET intermediate between the other two groups. 30017832 2018
Metastatic malignant neoplasm to brain
0.060 Biomarker disease BEFREE NCOA4-RET fusion was detected by FusionPlex using the resected brain metastatic tissue of CRC patient with solitary brain metastasis and then reconfirmed by fluorescence in situ hybridization (FISH) test. 30210625 2018
Metastatic malignant neoplasm to brain
0.060 GeneticVariation disease BEFREE We prospectively addressed whether EGFR and KRAS mutations, EML4-ALK, ROS1 and RET rearrangements, or wild-type (WT), affects radiosurgery outcomes and overall survival (OS) in non-small cell lung cancer (NSCLC) patients with brain metastases (BM). 26520640 2016
Metastatic malignant neoplasm to brain
0.060 AlteredExpression disease BEFREE Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. 25982012 2015